ARTICLE
7 November 2014

When Is The Presence Of Lactobacillus Acidophilus An Occurrence Under A CGL Policy?

FL
Foley & Lardner

Contributor

Foley & Lardner LLP looks beyond the law to focus on the constantly evolving demands facing our clients and their industries. With over 1,100 lawyers in 24 offices across the United States, Mexico, Europe and Asia, Foley approaches client service by first understanding our clients’ priorities, objectives and challenges. We work hard to understand our clients’ issues and forge long-term relationships with them to help achieve successful outcomes and solve their legal issues through practical business advice and cutting-edge legal insight. Our clients view us as trusted business advisors because we understand that great legal service is only valuable if it is relevant, practical and beneficial to their businesses.
In Wisconsin Pharmacal Co. v. Nebraska Cultures of California, the Wisconsin Court of Appeals analyzed the circumstances under which a supplier’s negligent provision of an incorrect ingredient to a manufacturer, where the ingredient renders the other ingredients and the final product unusable, constitutes an "occurrence" under a CGL policy.
United States Litigation, Mediation & Arbitration

In Wisconsin Pharmacal Co. v. Nebraska Cultures of California, No. 13AP613 (Wis. Ct. App. Oct. 29, 2014), the Wisconsin Court of Appeals analyzed the circumstances under which a supplier's negligent provision of an incorrect ingredient to a manufacturer, where the ingredient renders the other ingredients and the final product unusable, constitutes an "occurrence" under a commercial general liability (CGL) policy.

The dispute arose when a supplier mistakenly supplied the wrong ingredient to Wisconsin Pharmacal, which manufactured a "feminine health probiotic supplement" for a major retailer. The probiotic supplement was sold as a chewable tablet under the retailer's label. Wisconsin Pharmacal made the chewable tablets through what the court called a "tableting process"—that is, by combining a number of raw ingredients and pressing the resulting mixture into tablets.

One of the necessary ingredients of the tablet was Lactobacillus rhamnosus A, a bacterium used as a probiotic. Wisconsin Pharmacal contracted with a series of suppliers to obtain a "substantial quantity" of the bacteria. However, instead of supplying Lactobacillus rhamnosus A, the suppliers mistakenly supplied Lactobacillus acidophilus. That bacterium, once incorporated into the finished product, could not be extracted from the tablets, which became unusable. The retailer was forced to recall the supplement.

The only issue before the court of appeals was an insurance-coverage dispute. The court of appeals ultimately determined that the suppliers' CGL policies provided coverage, reversing the circuit court's summary-judgment decision in favor of the insurers.

The preliminary issue was whether there was a grant of coverage at all. In other words, was there "property damage caused by an occurrence"? The court said yes. The damage to the other ingredients in the supplement and the damage to the finished probiotic tablets themselves was "physical injury to tangible property" sufficient to trigger coverage. Furthermore, the court recognized that there was damage to "cartons, inserts, tooling, dies, and other property."

The court methodically addressed the insurers' multiple arguments that coverage did not exist, ranging from the policies' "business risk" exclusions to arguments based on the economic-loss doctrine's integrated product/component part framework.

Judge Reilly dissented. He believed that the case involved essentially misrepresentation claims. That is, the suppliers represented that they would provide Lactobacillus rhamnosus A, but instead they supplied Lactobacillus acidophilus. The Wisconsin Supreme Court has held that a misrepresentation is neither an accident nor an occurrence under a CGL policy. In Judge Reilly's view, the court had rewritten the CGL policy into a performance bond.

Barring review by the supreme court, the court's detailed discussion of the CGL policies will have broad ramifications in future disputes between suppliers and manufacturers.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More